Isis Stock Falls On Unusually High Volume (ISIS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Isis Pharmaceuticals (Nasdaq: ISIS) is trading at unusually high volume Wednesday with 3.1 million shares changing hands. It is currently at 2.2 times its average daily volume and trading down $2.24 (-10.2%) at $19.65 as of 4 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Isis has a market cap of $2.32 billion and is part of the health care sector and drugs industry. Shares are up 114.8% year to date as of the close of trading on Tuesday.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform.

TheStreet Ratings rates Isis as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full Isis Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Isis Pharmaceuticals Changes Its Name

Isis Pharmaceuticals Changes Its Name

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

ISIS Pharmaceuticals (ISIS) Weak On High Volume